郭艺芳:缘来缘去终结缘!我与高血压的不解之缘

2018-04-03 董杰 医师报

对于河北省人民医院副院长、老年病科主任郭艺芳教授来说,与高血压的不解之缘,是从最初的不情愿,到最终的“以身相许”。他勤于笔耕,将一篇篇前沿指南和临床试验的解读呈现给读者。他为人谦和,风趣幽默,且严于律己、宽以待人。每晚锻炼1小时,读文献1小时,说到做到。有时,偶发几首风花雪夜的小诗,聊以怡情——心晴四时皆春景,冬雨虽寒亦柔情。诗人痴醉不知季,错把落叶作落英。


《临江仙·结缘高血压

年少曾经梦缤纷,血压独未究询。缘去缘来终结缘。

天假其便时,为之付终身。

卒中心梗诸顽疾,此症皆为恶根。前辈已拓荆棘路。

我等当奋进,不负开路人!

——郭艺芳

对于河北省人民医院副院长、老年病科主任郭艺芳教授来说,与高血压的不解之缘,是从最初的不情愿,到最终的“以身相许”。他勤于笔耕,将一篇篇前沿指南和临床试验的解读呈现给读者。他为人谦和,风趣幽默,且严于律己、宽以待人。每晚锻炼1小时,读文献1小时,说到做到。有时,偶发几首风花雪夜的小诗,聊以怡情——心晴四时皆春景,冬雨虽寒亦柔情。诗人痴醉不知季,错把落叶作落英。

他是位有情怀的医者!

曾对高血压“不屑一顾”

1987 年,从河北医科大学毕业的郭艺芳来到河北省人民医院工作。那时的他,对风心病、冠心病、心衰、心律失常产生了浓厚的兴趣,唯独不把高血压看在眼里。

在他看来,高血压不过是一种普通的疾病,“舌下含一片心痛定就能解决问题”,根本没有“技术含量”。

当时,临床上可供使用的药物相对单一,几乎千篇一律都是心痛定、心得安或卡托普利治疗。能降下来便罢,降不下来就算了。刚工作时,郭艺芳把《内科学》教科书读得滚瓜烂熟,对于心衰、心肌梗死、心律失常等“重要疾病”的章节几乎倒背如流,“高血压”却被一带而过。

1989年,郭艺芳师从胡大一教授进行硕士学位课题研究时,顺其自然地对室性心律失常的电生理学与电药理学研究投入了主要精力,成了“发烧友”。

当时,国内对于心血管病的内科治疗手段还相对有限,但介入心脏病学已在国外如火如荼地展开,国内很多医生跃跃欲试,有机会成为介入治疗的医生非常令人羡慕。

那时,在郭艺芳心中,心脏介入工作就是阳春白雪,而进行高血压研究的是下里巴人。折返激动、触发激动、自律性增高、室速、室颤、射频消融等这些“高大上”的词汇不断在郭艺芳脑海里激荡,无暇顾及高血压。

有一次,老家一位患高血压的邻居写信,请郭艺芳帮忙联系北京的专家治疗。郭艺芳在回信中是这么说的:“高血压是很简单的一种病,不必来京治疗,吃几天心痛定和心得安就好了。实在降不下来也没关系,高一点就高一点吧”。

郭艺芳与高血压的缘分,似乎还没有开始就走到了尽头。

长久以来对于高血压“不屑一顾”的态度,也让他后来与高血压的第一次交集也略显淡漠。

1992 年,硕士研究生毕业的郭艺芳回到河北省人民医院。不久,他却因乏力、低热化验血常规,发现白细胞计数明显减低,且伴淋巴细胞比例严重增高,出院休息观察一个多月后,血象才恢复正常。

血液科专家建议,郭艺芳的这次血液检验异常可能与接触射线有关,以后不要再从事心脏介入工作。

这个诊断结果对郭艺芳来说是沉重的打击,伴随着失落与消沉,他调入了老年科。

河北省人民医院老年病科创建于1984年,是我国最早建立老年病科的少数几家医院之一。当时的学科带头人曲镭教授是我国著名老年医学专家和康复医学专家。1994年夏天,曲镭教授让郭艺芳去他办公室帮忙整理书籍,两人有了一次长谈。

“临床医生在完成日常工作的同时,也应该有意识地开展固定的研究工作。你是一名心内科医生,既然不能从事介入工作,就应该选择一个不需要介入的研究方向。”至今,郭艺芳仍清晰地记得曲教授的谆谆告诫,“高血压是一个不错的选择,这个病在老年患者中非常常见,并且危害很大,很值得研究。”

此后几个月,曲教授接连送给郭艺芳几部高血压书籍,结果却被他束之高阁。

彼时的郭艺芳仍旧停留在“心痛定、心得安与卡托普利”的概念里。

我国老年医学与老年心血管病康复医学奠基人之一曲镭教授赠送郭艺芳多部高血压书籍,这是曲镭教授第一次建议郭艺芳把高血压作为主要研究方向。

与高血压正式结缘

与高血压真正结缘,始于 1996 年,郭艺芳偶然阅读了一篇关于时间生物学的文章,对心血管系统生物节律研究产生了浓厚兴趣。之后几年里,他完成了数项心率、房室传导功能和血压的昼夜节律研究,获得两项河北省科技进步奖。2003年,他在《美国心脏杂志》发表综述文章,系统地描述了心血管系统以及心血管病的时间生物学特征。

随着对动态血压监测数据分析的增多,郭艺芳逐渐感觉到血压绝对不是一个简单的概念,除了诊室血压测量外,血压背后还存在很多奥秘有待揭晓。由此开始,他对血压的关注逐渐增多:从诊室血压到动态血压、从昼夜节律到血压变异、从降压药物的服药时间到高血压的时间治疗学……所有这一切都值得深入研究,研究兴趣一发不可收拾。

2002 年,郭艺芳逐渐把研究重点由人体的动态血压监测研究转向动物实验,先后以不同光照方案、不同种类降压药物以及不同用药时间为干预因素,探讨了哺乳动物肾素-血管紧张素-醛固酮系统与儿茶酚胺等血管活性物质的昼夜节律现象,取得了一系列成绩。至此,郭艺芳对高血压有了更深的认识。

追逐高血压的循证医学步伐

上世纪 80 年代末,大型随机化临床试验对临床实践的影响越来越大,医学模式正由经验医学向循证医学转变。但郭艺芳对很多研究几乎一无所知,他认为作为一名临床医生,只需要管好患者、做好研究。

2007年,以糖尿病患者为基础所进行的ADVANCE 研究降压治疗试验结果公布。直到有一天,某药企代表带着 ADVANCE 研究资料向郭艺芳介绍:“这项研究证明,所有糖尿病患者,无论有无高血压均可以服用这种降压药。如果仅全球一半的糖尿病患者应用这种药物,每五年将至少可挽救100万人的生命”,引起了他的质疑。逐字逐句研读全文后,他将对此研究的理解通过纸媒和网络进行了发表。

自此,郭艺芳对高血压及相关疾病的大型临床试验产生了浓厚兴趣,真正走上了高血压循证医学之路。两个月,他一口气阅读了几十项降压治疗临床试验的研究全文,发现高血压领域竟然存在如此多的争议与未知。

正是从这个时期开始,郭艺芳养成了一个新习惯:每晚休息前1小时阅读文献,第一时间掌握最新进展。随着微博、微信的兴起,他总会及时将有意义的新研究或新指南要点整理成短文,通过微博或微信发布出去。

随着对高血压的兴趣日渐浓厚,郭艺芳更加积极地参与关于高血压及相关疾病的学术活动,更多机会接触到刘力生、吴兆苏、王文、赵连友、孙宁玲、张维忠等高血压领域的前辈专家,并得到多方指导与帮助,使得郭艺芳对于高血压的认识进一步深入。

自1994年起,郭艺芳在国内率先开展了心血管系统生物节律的研究工作,例如通过对持续性房颤患者心室率的动态心电图监测研究,首次证实房室传导功能存在明显的近日节律性。他先后代表中国医师协会心血管内科医师分会、中华医学会心血管病学分会、中国老年学学会心脑血管病专业委员会等学术机构执笔撰写了多部指南性文件。

从最初的旁观者到如今多部高血压共识、指南的撰写者,他说:“我与高血压结缘是一次又一次的偶然,但为高血压防治贡献毕生精力则是必然。在高血压防治研究上,我仍是一个需要不断学习的‘新兵’。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=302595, encodeId=f85c30259561, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Apr 04 07:26:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302573, encodeId=cf583025e36b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Apr 04 07:03:10 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302543, encodeId=d7cc30254328, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Apr 04 06:04:09 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302535, encodeId=437330253561, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Wed Apr 04 05:17:42 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302521, encodeId=60fc302521d6, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Apr 04 00:31:05 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302517, encodeId=b6da30251e71, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Apr 04 00:27:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302510, encodeId=30d430251070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Wed Apr 04 00:25:35 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302500, encodeId=ea0f3025007f, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Apr 04 00:22:33 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 1dd8c52fm63(暂无匿称)

    了解了解.学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=302595, encodeId=f85c30259561, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Apr 04 07:26:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302573, encodeId=cf583025e36b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Apr 04 07:03:10 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302543, encodeId=d7cc30254328, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Apr 04 06:04:09 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302535, encodeId=437330253561, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Wed Apr 04 05:17:42 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302521, encodeId=60fc302521d6, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Apr 04 00:31:05 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302517, encodeId=b6da30251e71, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Apr 04 00:27:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302510, encodeId=30d430251070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Wed Apr 04 00:25:35 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302500, encodeId=ea0f3025007f, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Apr 04 00:22:33 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 张新亮1853311252142e2fm

    好文献学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=302595, encodeId=f85c30259561, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Apr 04 07:26:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302573, encodeId=cf583025e36b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Apr 04 07:03:10 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302543, encodeId=d7cc30254328, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Apr 04 06:04:09 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302535, encodeId=437330253561, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Wed Apr 04 05:17:42 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302521, encodeId=60fc302521d6, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Apr 04 00:31:05 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302517, encodeId=b6da30251e71, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Apr 04 00:27:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302510, encodeId=30d430251070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Wed Apr 04 00:25:35 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302500, encodeId=ea0f3025007f, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Apr 04 00:22:33 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 changjiu

    学习一下谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=302595, encodeId=f85c30259561, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Apr 04 07:26:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302573, encodeId=cf583025e36b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Apr 04 07:03:10 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302543, encodeId=d7cc30254328, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Apr 04 06:04:09 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302535, encodeId=437330253561, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Wed Apr 04 05:17:42 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302521, encodeId=60fc302521d6, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Apr 04 00:31:05 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302517, encodeId=b6da30251e71, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Apr 04 00:27:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302510, encodeId=30d430251070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Wed Apr 04 00:25:35 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302500, encodeId=ea0f3025007f, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Apr 04 00:22:33 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 yjs木玉

    学习学习再学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=302595, encodeId=f85c30259561, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Apr 04 07:26:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302573, encodeId=cf583025e36b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Apr 04 07:03:10 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302543, encodeId=d7cc30254328, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Apr 04 06:04:09 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302535, encodeId=437330253561, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Wed Apr 04 05:17:42 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302521, encodeId=60fc302521d6, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Apr 04 00:31:05 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302517, encodeId=b6da30251e71, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Apr 04 00:27:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302510, encodeId=30d430251070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Wed Apr 04 00:25:35 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302500, encodeId=ea0f3025007f, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Apr 04 00:22:33 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 飛歌

    学习了很有用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=302595, encodeId=f85c30259561, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Apr 04 07:26:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302573, encodeId=cf583025e36b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Apr 04 07:03:10 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302543, encodeId=d7cc30254328, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Apr 04 06:04:09 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302535, encodeId=437330253561, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Wed Apr 04 05:17:42 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302521, encodeId=60fc302521d6, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Apr 04 00:31:05 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302517, encodeId=b6da30251e71, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Apr 04 00:27:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302510, encodeId=30d430251070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Wed Apr 04 00:25:35 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302500, encodeId=ea0f3025007f, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Apr 04 00:22:33 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 秀红

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=302595, encodeId=f85c30259561, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Apr 04 07:26:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302573, encodeId=cf583025e36b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Apr 04 07:03:10 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302543, encodeId=d7cc30254328, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Apr 04 06:04:09 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302535, encodeId=437330253561, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Wed Apr 04 05:17:42 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302521, encodeId=60fc302521d6, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Apr 04 00:31:05 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302517, encodeId=b6da30251e71, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Apr 04 00:27:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302510, encodeId=30d430251070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Wed Apr 04 00:25:35 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302500, encodeId=ea0f3025007f, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Apr 04 00:22:33 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 121832a9m88暂无昵称

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=302595, encodeId=f85c30259561, content=了解了解.学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Wed Apr 04 07:26:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302573, encodeId=cf583025e36b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Wed Apr 04 07:03:10 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302543, encodeId=d7cc30254328, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Wed Apr 04 06:04:09 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302535, encodeId=437330253561, content=学习学习再学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Wed Apr 04 05:17:42 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302521, encodeId=60fc302521d6, content=学习了很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib3IzoRn621JdKCFUI4XvNELcibocrAVU6aUzEVDSaf3rYH08PUYUiagGqxAEhj8g9WqqNvD1CupIpCrmnR2OrqHZh/0, createdBy=7f181365728, createdName=飛歌, createdTime=Wed Apr 04 00:31:05 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302517, encodeId=b6da30251e71, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/01/15/8213228fe923915543544ad3da7e1c64.jpg, createdBy=6bd82014262, createdName=秀红, createdTime=Wed Apr 04 00:27:13 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302510, encodeId=30d430251070, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f22260741, createdName=121832a9m88暂无昵称, createdTime=Wed Apr 04 00:25:35 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302500, encodeId=ea0f3025007f, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Wed Apr 04 00:22:33 CST 2018, time=2018-04-04, status=1, ipAttribution=)]
    2018-04-04 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

相关资讯

郭艺芳教授:谨慎解读SPRINT研究结果!

郭艺芳教授随着SPRINT研究详细数据的发表,必将引起广泛关注,并再次激起国内外学者对于最佳血压控制目标的热烈讨论。详细数据尚未完全公布仅凭研究者初步公布的部分终点获益难以得出最终结论。通过对受试者详细信息、特别是不同亚组(如年龄、性别、血压水平、既往治疗史、并存疾病或危险因素情况、高血压病程等)患者特征以及两组之间安全性指标与不良反应事件进行深入分析,方能得出更为肯定的结论。任何单项临床研究都难

郭艺芳:近日心血管病领域的几个热点话题

近日,心血管病领域有以下几个话题值得关注:1.SPRINT研究引起的震荡SPRINT研究的提前结束,在国内外学术界以及大众媒体引起空前关注,并再次激起了已经纠结多年的降压治疗目标值的问题。一时间,人们纷纷争论究竟应该把血压控制在140 mm Hg还是120 mm Hg。实际上,这种争论不会有结果,即便再有几项、甚至几十项研究也不会得出明确结论,因为不会有一个适合于所有高血压患者的理想目标值。不同特

郭艺芳:SGLT-2抑制剂——具有降糖作用的降压药

2015年EASD年会期间公布EMPA-REG研究结果以后,迅即在囯内外引起广泛关注。该研究显示,在常规治疗基础上应用SGLT-2抑制剂恩格列净治疗,可显著降低确诊心血管疾病的2型糖尿病患者的心血管死亡率与全因死亡率。因为这是首项证实降糖药物可以降低临床心血管终点事件发生率的临床研究,因而被视为具有里程碑意义的降糖药物试验。然而迄今为止,关于恩格列净的获益机制仍然莫衷一是。目前可以肯定的是,血糖水

ESC 2014:郭艺芳:RDN治疗顽固性高血压何去何从?

肾脏去交感神经治疗(RDN)顽固性高血压技术何去何从?本届ESC年会期间公布了SYMPLICITY HTN-3研究的1年随访结果,仍未发现该技术可使血压降低。目前应如何对待此技术?来自河北省人民医院郭艺芳教授近日在其微博上做了简要的分析,以下为详细内容。近年来,肾脏去交感神经术(RDN)治疗顽固性高血压一直备受关注。 早期研究显示,RDN可以有效降低顽固性高血压患者的血压水平,因而被视为

郭艺芳:检测微量白蛋白尿真的应该退出历史舞台了吗?

2014年美国糖尿病协会(ADA)年会期间,美国哈佛大学著名学者Krolewski指出:“微量白蛋白尿(MAU)不能作为早期、进行性肾功能下 降的指标,到了用其他指标替代的时候了”,其理由是部分1期和2期慢性肾病患者并不能检测出MAU,这使得不伴MAU的早期肾功能下降患者或有可能发展为 终末期肾病的患者不能得到早期干预和治疗。基于Krolewski教授的观点,国内外很多学者认为通过检测MAU评

GW-ICC 2016:郭艺芳谈心衰合并COPD,β受体阻滞剂使用率低

β受体阻滞剂是慢性心衰药物治疗的基石,长期充分地应用β受体阻滞剂治疗可显著降低慢性心衰患者的心血管事件风险、再住院率以及死亡率。然而,近日发表在《Heart》杂志上的一项研究结果却表明,大量的心衰合并慢性阻塞性肺病(COPD)患者并未接受β受体阻滞剂治疗。研究共纳入89861例 COPD患者、24237例心衰患者和10853例心衰合并COPD患者。心衰合并COPD患者的平均年龄为79 岁,其中